Company Overview

Anteris Technologies Global Corp. is a clinical-stage structural heart company focused on developing and commercializing advanced medical devices for the treatment of cardiovascular disease, particularly aortic valve disease. The company operates within the medical device and cardiovascular therapeutics industries, with a core emphasis on transcatheter heart valve replacement technologies.

The company’s primary business is the development of the DurAVR® Transcatheter Heart Valve (THV), which is designed to address durability, hemodynamic performance, and patient outcomes in the treatment of severe aortic stenosis. Anteris serves interventional cardiologists, cardiac surgeons, and healthcare systems treating structural heart disease. Its strategic positioning is centered on proprietary biomaterials technology intended to replicate native valve performance more closely than existing solutions. The company originated from cardiovascular assets previously held within Admedus Ltd. and was restructured and rebranded as Anteris Technologies in 2021 to focus exclusively on heart valve innovation.

Business Operations

Anteris operates primarily as a research, development, and early-stage commercialization organization. Its business model is driven by product development milestones, clinical trial progression, regulatory approvals, and, ultimately, commercialization or strategic partnerships. The company currently reports a single operating segment focused on structural heart solutions, with the DurAVR® product platform representing its core asset and revenue driver once commercialized.

Operations span preclinical research, clinical development, manufacturing process development, and regulatory engagement. Anteris controls proprietary tissue engineering and valve-shaping technologies used in the DurAVR® platform. The company conducts clinical trials and collaborates with external manufacturing and clinical research organizations. Based on publicly available disclosures, Anteris does not currently operate revenue-generating commercial subsidiaries; data inconclusive based on available public sources regarding active joint ventures.

Strategic Position & Investments

Anteris’s strategic direction is focused on advancing the DurAVR® THV system through global clinical trials and securing regulatory approvals in major markets, including the United States and Europe. Growth initiatives prioritize demonstrating long-term valve durability and improved patient outcomes to differentiate the technology from incumbent transcatheter aortic valve replacement products.

The company has historically rationalized its asset base to concentrate on core cardiovascular technologies. Notable past transactions include the divestment of non-core vascular graft businesses to fund development of DurAVR®. Investment activity is primarily directed toward R&D, clinical trial execution, manufacturing scale-up, and intellectual property protection. Anteris is not currently diversified across unrelated sectors, and its strategic focus remains tightly aligned with structural heart innovation.

Geographic Footprint

Anteris maintains a multinational operating footprint, with corporate and development activities spanning North America, Australia, and Europe. The company is headquartered in the United States, while maintaining significant research, development, and manufacturing capabilities in Australia. Clinical and regulatory activities extend into Europe, supporting global trial enrollment and market access strategies.

This geographic structure enables Anteris to access key clinical trial sites, regulatory agencies, and capital markets across multiple regions. Its international presence supports long-term plans for global commercialization of the DurAVR® platform, subject to regulatory approval.

Leadership & Governance

Anteris is led by an executive team with experience in cardiovascular medical devices, clinical development, and global commercialization. Leadership emphasizes disciplined capital allocation, clinical evidence generation, and long-term value creation through differentiated technology.

Key executives include:

• Wayne Paterson – President and Chief Executive Officer
• John Quayle – Chief Financial Officer
• Dr. Paul Healy – Chief Technology Officer
• Bradley J. Farrell – Chief Operating Officer

The company’s governance framework is structured to support regulatory compliance across multiple jurisdictions and aligns management incentives with clinical and shareholder outcomes.